Abbott’s New Leadless Pacemaker Receives FDA Approval for Slow Heart Rhythms

Every year, more than one million cardiac pacemakers are implanted worldwide, and over 200,000 of these occur in the US.

Abbott Laboratories announced on Monday that the US Food and Drug Administration (FDA) approved its Aveir™ single-chamber (VR) leadless pacemaker system. The Illinois-based company received the FDA nod for its new pacemaker to treat patients with bradycardia (slow heart rhythms).